Eurofins CDMO Alphora Secures Funding for Next-Gen ADC Production
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy ?
Source: Businesswire
- R&D Collaboration: Eurofins CDMO Alphora has secured funding from the National Research Council of Canada Industrial Research Assistance Program to advance next-generation antibody-drug conjugate (ADC) production, addressing the growing demand for targeted therapeutics.
- Technological Innovation: The project collaborates with Daresbury Proteins Ltd. to develop a high-yield expression platform that integrates optimized affinity peptide tags directly into monoclonal antibody production, streamlining the ADC manufacturing process and reducing complexity and costs.
- Accelerated Development Cycles: The new platform is designed to eliminate several traditional conjugation and purification steps, thereby accelerating ADC development timelines and laying the groundwork for future production of clinic-ready ADCs, enhancing efficiency across clinical and commercial supply chains.
- Economic Development Impact: By leveraging Eurofins CDMO Alphora's capabilities in complex drug development and manufacturing, the project is expected to drive innovative solutions, foster high-skilled job creation, and bolster Canada's capacity to produce the next wave of precision biologics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
